Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 Akedo Akedo +48.65%
#3 DOVU DOVU +48.14%
#4 Velvet Velvet +43.34%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cross Cross +24.30%
#7 Cap Cap +20.40%
#8 DoubleZero DoubleZero +15.97%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.98%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +9.29%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
Rang in Aktien #39565
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Aktienkurs
$0.003084
Marktkapitalisierung
$434.03K
Veränderung (1 Tag)
-7.14%
Veränderung (1 Jahr)
-89.24%
Land
BE
Handel Oxurion N.V. (OXUR)

Kategorie

Healthcare
P/S-Verhältnis für Oxurion N.V. (OXUR)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Oxurion N.V. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Oxurion N.V. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE